APA (7th ed.) Citation

Hernando, J., Garcia-Alvarez, A., Castaneda, D. M., Eyzaguirre, D. A., Garcia, M. D., Gonzalez, N. S., . . . Capdevila, J. (2020). 1186P Impact of temozolomide (TEM) and capecitabine (CAP) dose reductions in toxicity and efficacy in patients (pts) with neuroendocrine neoplasms (NENs) treated with CAPTEM chemotherapy. Annals of Oncology, 31, S782. https://doi.org/10.1016/j.annonc.2020.08.1399

Chicago Style (17th ed.) Citation

Hernando, J., et al. "1186P Impact of Temozolomide (TEM) and Capecitabine (CAP) Dose Reductions in Toxicity and Efficacy in Patients (pts) with Neuroendocrine Neoplasms (NENs) Treated with CAPTEM Chemotherapy." Annals of Oncology 31 (2020): S782. https://doi.org/10.1016/j.annonc.2020.08.1399.

MLA (9th ed.) Citation

Hernando, J., et al. "1186P Impact of Temozolomide (TEM) and Capecitabine (CAP) Dose Reductions in Toxicity and Efficacy in Patients (pts) with Neuroendocrine Neoplasms (NENs) Treated with CAPTEM Chemotherapy." Annals of Oncology, vol. 31, 2020, p. S782, https://doi.org/10.1016/j.annonc.2020.08.1399.